Movement Alert｜Boston Scientific Rises 3.16% in After-Hours Trading, Technical Rebound as Most Institutions Maintain Buy Ratings Despite Target Cuts

Market Focus08-06

On August 6, Boston Scientific rose 3.16% in after-hours trading, trading at approximately $49.27/share, with turnover of $22.47 million. The rebound followed a 3.03% decline in the prior session driven by full-year guidance cuts and multiple analyst target price reductions.

Despite lowering targets, most covering institutions maintained buy ratings. Deutsche Bank cut its target to $60 from $75, UBS to $67 from $74, and RBC to $70 from $85, all retaining buy-equivalent ratings. UBS noted the company has underappreciated growth drivers beyond its challenged Watchman and electrophysiology franchises, including coronary intravascular lithotripsy, renal denervation products expected in 2027-2028 representing a combined $2.5 billion served market, and the Empower leadless pacemaker launch in 2027. UBS argued current share pricing implies sales declines through 2029, a scenario it views as excessively pessimistic given the company's diversified pipeline.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1175371914?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-06 04:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1175371914","market":"us","top_or_hot":-1,"title":"Movement Alert｜Boston Scientific Rises 3.16% in After-Hours Trading, Technical Rebound as Most Institutions Maintain Buy Ratings Despite Target Cuts","media":"Market Focus","content":"<p><p>On August 6, Boston Scientific rose 3.16% in after-hours trading, trading at approximately $49.27/share, with turnover of $22.47 million. The rebound followed a 3.03% decline in the prior session driven by full-year guidance cuts and multiple analyst target price reductions.</p><p>Despite lowering targets, most covering institutions maintained buy ratings. Deutsche Bank cut its target to $60 from $75, UBS to $67 from $74, and RBC to $70 from $85, all retaining buy-equivalent ratings. UBS noted the company has underappreciated growth drivers beyond its challenged Watchman and electrophysiology franchises, including coronary intravascular lithotripsy, renal denervation products expected in 2027-2028 representing a combined $2.5 billion served market, and the Empower leadless pacemaker launch in 2027. UBS argued current share pricing implies sales declines through 2029, a scenario it views as excessively pessimistic given the company's diversified pipeline.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Boston Scientific Rises 3.16% in After-Hours Trading, Technical Rebound as Most Institutions Maintain Buy Ratings Despite Target Cuts</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Boston Scientific Rises 3.16% in After-Hours Trading, Technical Rebound as Most Institutions Maintain Buy Ratings Despite Target Cuts\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-06 04:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 6, Boston Scientific rose 3.16% in after-hours trading, trading at approximately $49.27/share, with turnover of $22.47 million. The rebound followed a 3.03% decline in the prior session driven by full-year guidance cuts and multiple analyst target price reductions.</p><p>Despite lowering targets, most covering institutions maintained buy ratings. Deutsche Bank cut its target to $60 from $75, UBS to $67 from $74, and RBC to $70 from $85, all retaining buy-equivalent ratings. UBS noted the company has underappreciated growth drivers beyond its challenged Watchman and electrophysiology franchises, including coronary intravascular lithotripsy, renal denervation products expected in 2027-2028 representing a combined $2.5 billion served market, and the Empower leadless pacemaker launch in 2027. UBS argued current share pricing implies sales declines through 2029, a scenario it views as excessively pessimistic given the company's diversified pipeline.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BSX","symbol_name":"波士顿科学","start_time":0,"source_url":"","article_id":"1175371914","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1175371914","pubTimestamp":1785961171,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 6, Boston Scientific rose 3.16% in after-hours trading, trading at approximately $49.27/share, with turnover of $22.47 million. The rebound followed a 3.03% decline in the prior session...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BSX":"波士顿科学"},"translate_title":"走势警报|波士顿科学盘后交易上涨3.16%，尽管目标下调，大多数机构仍维持买入评级，技术反弹","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BSX":1},"content_text":"On August 6, Boston Scientific rose 3.16% in after-hours trading, trading at approximately $49.27/share, with turnover of $22.47 million. The rebound followed a 3.03% decline in the prior session driven by full-year guidance cuts and multiple analyst target price reductions.Despite lowering targets, most covering institutions maintained buy ratings. Deutsche Bank cut its target to $60 from $75, UBS to $67 from $74, and RBC to $70 from $85, all retaining buy-equivalent ratings. UBS noted the company has underappreciated growth drivers beyond its challenged Watchman and electrophysiology franchises, including coronary intravascular lithotripsy, renal denervation products expected in 2027-2028 representing a combined $2.5 billion served market, and the Empower leadless pacemaker launch in 2027. UBS argued current share pricing implies sales declines through 2029, a scenario it views as excessively pessimistic given the company's diversified pipeline.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1175371914","isCrawlerRequest":true}